|Titre :||The ASAM national practice guideline for the use of medications in the treatment of addiction involving opioid use|
|Auteurs :||American Society of Addiction Medicine|
|Type de document :||Rapport|
|Editeur :||Chevy Chase, MD : ASAM (American Society of Addiction Medicine, Inc.), 2015|
|Format :||170 p.|
|Discipline :||TRA (Traitement et prise en charge / Treatment and care)|
Thésaurus TOXIBASETRAITEMENT ; RECOMMANDATION ; OPIOIDES ; MEDICAMENTS ; HEROINE ; PHARMACOTHERAPIE ; DIAGNOSTIC ; SEVRAGE ; TRAITEMENT DE MAINTENANCE ; SUBSTITUTION ; BUPRENORPHINE ; NALTREXONE
The Practice Guideline will assist clinicians prescribing pharmacotherapies to patients with addiction related to opioid use. It addresses knowledge gaps about the benefits of treatment medications and their role in recovery, while guiding evidence-based coverage standards by payers.
The Practice Guideline is a timely resource as the United States is currently experiencing an opioid epidemic. According to the National Institute on Drug Abuse (NIDA), 2.1 million Americans live with pain reliever opioid addiction disease, while 467,000 Americans live with heroin opioid addiction disease. Overdose deaths are now comparable to the number of deaths caused by motor vehicle crashes, and the societal costs of opioid misuse is estimated to be above $55 billion per year.
Medications are both clinical and cost-effective interventions. While the effectiveness of medications has been researched and documented, their utilization is low and coverage varies dramatically. Less than 30% of treatment programs offer medications and less than half of eligible patients in those programs receive medications. [Extracts from the press release]
|Domaine :||Autres substances / Other substances ; Drogues illicites / Illicit drugs|
|Sous-type de document :||Guide pratique / Manual|
|Refs biblio. :||173|